Predicting Response to Therapy | Accelerating Clinical Trials

At Cellular Analytics, our comprehensive technological solutions accelerate drug development and commercialization by providing valuable insight on patient subpopulations.  Our proprietary non-invasive approach allows us to capture, identify, and analyze proteins on all tumor and immune cells at the single-cell level and link response to patient phenotype.

CytoFind will alter the therapeutic landscape by improving drug compatibility, ultimately increasing patient survival. This approach is not incremental, but rather a quantum improvement that will produce real value for Cellular Analytics partners.

Cellular Analytics obtained seed funding from FACIT and is affiliated with MaRS and Johnson & Johnson Innovation (JLABS). 



To learn more about CytoFind, please download the technology brief. 

If you are interested in partnering with our team, please contact us.

MaRS Centre - West Tower, 661 University Ave,

Suite 1300, Toronto, ON, M5G 0B7

© 2019 by Cellular Analytics.